Expanding the possibilities of treatment and prevention of venous thromboembolic complications in cancer patients. The role of oral anticoagulants

Improving the quality of care for patients with oncological diseases due to the improvement of methods of chemoradiotherapy and surgical interventions, accessibility and modernization of diagnostic potential, is accompanied by a steady increase in the frequency of venous thromboembolic complications, which occupy one of the leading places among the causes of death.

Patients with oncological diseases are subject to various risk factors for thromboembolic complications, which are caused by the presence of a malignant neoplasm, due to the development of many coagulation abnormalities, initiating not only an increased tendency to thrombosis, but also a tendency to bleeding. Cancer-associated venous thrombosis, growing out of the framework of certain medical specialties, act as comorbid pathological conditions that require an interdisciplinary approach in developing rational methods of prevention and treatment. Improving the understanding of the pathophysiological mechanisms of venous thrombosis in cancer patients contributes to the development of modern methods of prevention and treatment, among which anticoagulant therapy plays a dominant role. The appearance of oral anticoagulants on the pharmaceutical market, the effectiveness and safety of which is confirmed by a series of randomized clinical trials, opens up new prospects for improving the quality of life and long-term survival in patients with malignant neoplasms.

1. Farge D., Frere C., Connors J.M. et al. International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 International Clinical Practice Guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 2022;23(7):e334–47. DOI: 10.1016/S1470-2045(22)00160-7

2. Sushinskaya T.V., Stuklov N.I., Dobrokhotova Yu.E. Hemostasis and cancer-associated thrombosis: modern prevention and treatment. Onkologiya. Zhurnal im. P.A. Gertsena = P.A. Herzen Journal of Oncology 2018;4:64–72. (In Russ.). DOI: 1017116/onkolog20187464

3. Plokhova E.V., Dundua D.P. Thrombosis in patients with malignancy. Kardiologiya = Kardiologiia 2018;58(9S):19–28. (In Russ.). DOI: 10.18087/cardio.2523

4. Piccioli A., Prandoni P. Idiopathic venous thromboembolism as a first manifestation of cancer. Haemostasis 2001;31(1):37–9. PMID: 11990473

5. Robin P., Carrier M. Revisiting occult cancer screening in patients with unprovoked venous thromboembolism. Thromb Res 2018;164(1):7–11. DOI: 10.1016/j.thromres.2017.12.024

6. Shaib W., Deng Y., Zilterman D. et al. Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res 2010;30(10):4261–4. PMID: 21036750

7. Ashrani A.A., Marks R.S., Petterson T.M. et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood 2014;123(25):3972–8. DOI: 10.1182/blood-2014-01-549733

8. Khorana A.A., Francis C.W., Culakova E. et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5(3):632–4. DOI: 10.1111/j.1538–7836.2007.02374.x

9. Barsam S.J., Patel R., Arya R. Anticoagulation for prevention and treatment of cancer-related venous thromboembolism. Br J Haematol 2013;161(6):764–77. DOI: 10.1111/bjh.12314

10. Trousseau A. Clinique Médicale de L’hôtel-dieu de Paris. 2nd ed. Vol. 3. Phlegmatia alba dolens. Paris, France: J.-B. Baillière et fils, 1865. Pp. 654–712.

11. Falanga A., Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie 2012;32(2):115–25. DOI: 10.5482/ha-1170

12. Monreal M., Falga C., Valdes M. et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006;4(9):1950–6. DOI: 10.1111/j.1538-7836. 2006.02082.x

13. Falanga A., Marchetti M., Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost 2013;11(2): 223–33. DOI: 10.1111/jth.12075

14. Sørensen H.T., Mellemkjær L., Olsen L.H. et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343(25):1846–50. DOI: 10.1056/NEJM200012213432504

15. Bounameaux H., Haas S., Farjat A.E. et al. Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. Thromb Res 2020;191:103–12. DOI: 10.1016/j.thromres.2020.04.036

16. Jemal А., Bray F., Centeretal M.M. Global cancer statistics. CA Cancer J Clin 2011;61(2):69–90. DOI: 10.3322/caac.20107

17. Li M., Guo Q., Hu W. Incidence, risk factors, and outcomes of venous thromboembolism after oncologic surgery: a systematic review and meta-analysis. Thromb Res 2019;173:48–56. DOI: 10.1016/j.thromres.2018.11.012

18. Mulder F.I., Candeloro M., Kamphuisen P.W. et al. The khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica 2019;104(6):1277–87. DOI: 10.3324/haematol.2018.209114

19. Key N.S., Khorana A.A., Kuderer N.M. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020;38(5):496–520. DOI: 10.1200/JCO.19.01461

20. Blom J.W., Vanderschoot J.P.M., Oostindier M.J. et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006;4(3):529–35. DOI: 10.1111/j.1538-7836.2006.01804.x

21. Ay C., Dunkler D., Marosi C. et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;116(24):5377–82. DOI: 10.1182/blood-2010-02-270116

22. Rickles F.R. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb 2006;35(1–2):103–10. DOI: 10.1159/000093551

23. Agnelii G., Verso M. Thromboprophylaxis during chemotherapy in patients with advanced cancer. Thromb Res 2010;125(2):17–20. DOI: 10.1016/S0049-3848(10)70007-4

24. Khorana A.A. Venous thromboembolism and prognosis in cancer. Thromb Res 2010;125(6):490–3. DOI: 10.1016/j.thromres.2009.12.023

25. Somonova O.V., Elizarova A.L., Blindar V.N. et al. Treatment of cancer-related thrombosis: from recommendations to real clinical practice. Sovremennaya onkologiya = Journal of Modern Oncology 2019; 21(1):60–5. (In Russ.). DOI: 10.26442/18151434.2019.1.190247

26. Riedl J., Hell L., Kaider A. et al. Association of platelet activation markers with cancer-associated venous thromboembolism. Platelets 2016;27(1):80–5. DOI: 10.3109/09537104.2015.1041901

27. Falanga A., Marchetti M. Hemostatic biomarkers in cancer progression. Thromb Res 2018;164(1):54–61. DOI: 10.1016/j.thromres.2018.01.017

28. Riedl J., Preusser M., Nazari P.M. et al. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood 2017;129(13):1831–9. DOI: 10.1182/blood-2016-06-720714

29. Rickles F.R. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb 2006;35(1–2):103–10. DOI: 10.1159/000093551

30. Demers M., Wagner D.D. Neutrophil extracellular traps: a new link to cancer-associated thrombosis and potential implications for tumor progression. Oncoimmunology 2013;2(2):e22946. DOI: 10.4161/onci.22946

31. Rak J., Yu J.L., Luyendyk J. et al. Oncogenes, Trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Research 2006;66(22):10643–6. DOI: 10.1158/0008-5472.CAN-06-2350

32. Prandoni P. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100(10):3484–8. DOI: 10.1182/blood-2002-01-0108

33. Kakkos S.K., Gohel M., Baekgaard N. et al. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg 2021;61(1):9–82. DOI: 10.1016/j.ejvs.2020.09.023

34. Jara-Palomares L., Otero R., Jimenez D. et al. Development of a risk prediction score for occult cancer in patients with VTE. Chest 2017;151(3):564–71. DOI: 10.1016/j.chest.2016.10.025

35. Zhou M., Zhang L., Ding Y. et al. Extensive screening for occult malignancy in unprovoked venous thromboembolism: a metaanalysis. Thromb Res 2017;157:147–53. DOI: 10.1016/j.thromres.2017.07.019

36. Zamorano J.L., Lancellotti P., Muñoz D.R. et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines. Kardiologia Polska 2016;74(11):1193–233. DOI: 10.5603/KP.2016.0156

37. Draft clinical recommendations of the Association of Phlebologists of Russia “Deep vein thrombosis of extremities”, 2022. https://phlebounion.ru/recommendations/proyekt-kr-tgv-mz-rf-20.

38. Streiff M.B., Holmstrom B., Angelini D. et al. Cancer-associated venous thromboembolic disease, Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2021;19(10):1181–201. DOI: 10.6004/jnccn.2021.0047

39. Carrier M., Prandoni P. Controversies in the management of cancer-associated thrombosis. Expert Rev Hematol 2017;10(1):15–22. DOI: 10.1080/17474086.2017.1257935

40. Vedovati M., Germini F., Agnelli G. et al. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015;147(2):475–83. DOI: 10.1378/chest.14-0402

41. Raskob G.E., van Es N., Verhamme P. et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018;378(7):615–24. DOI: 10.1056/NEJMoa1711948

42. Young A.M., Marshall A., Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D). J Clin Oncol 2018;36(20):2017–23. DOI: 10.1200/JCO.2018.78.8034

43. McBane R.D. 2nd, Wysokinski W.E., Le-Rademacher J.G. et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020;18(2):411–21. DOI: 10.1111/jth.14662

44. Ageno W., Vedovati M.C., Cohen A. et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thromb Haemost 2021;121(5):616–24. DOI: 10.1055/s-0040-1720975

45. Stevens S.M., Woller S.C., Kreuziger L.B. et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 2021;160(6):2247–59. DOI: 10.1016/j.chest.2021.07.056

46. Carrier M., Blais N., Crowther M. et al. Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus. Curr Oncol 2018;25(5):329–37. DOI: 10.3747/co.25.4266

47. Katelnitskaya O.V., Kit O.I., Katelnitsky I.I. et al. Features of anticoagulant therapy of venous thromboembolism in patients with cancer. Flebologiya = Flebologiya 2020;14(2):135–41. (In Russ.). DOI: 10.17116/flebo202014021135

48. Riess H., Prandoni P., Harder S. et al. Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: potential for drug-drug interactions. Crit Rev Oncol Hematol 2018;132:169–79. DOI: 10.1016/j.critrevonc.2018.09.015

49. Cuker A., Arepally G.M., Chong B.H. et al. American society of hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2018;2(22):3360–92. DOI: 10.1182/bloodadvances.2018024489